Pfizer Endows Distinguished Chair in Pharmacy
(Released: June 23, 2004)
Robert McCarthy, Pharmacy Dean (860) 486-2129
Janice Palmer, UConn Communications (860) 486-0715
STORRS, Conn. — The University of Connecticut's School of Pharmacy received
a $2 Million gift today from Pfizer Global Research and Development, a division
of Pfizer Inc., to endow the school's first distinguished chair. It is the largest
single gift ever received by the school and is the first such endowment Pfizer has
made in the United States.
Establishment of the Pfizer Distinguished Endowed Chair in Pharmaceutical Technology
will enable the school to appoint a nationally recognized researcher, scholar and
teacher who has made significant contributions to the field of pharmaceutical technology,
the applied science for development of dosage forms.
The announcement was made during a ceremony held this morning in the shadow
of the new $87 million, 220,000 square-foot Pharmacy/Biology Building currently
under construction on the Storrs campus.
"Endowed chairs are established by great schools and colleges of pharmacy to
attract the best teachers and scholars," said Robert McCarthy, dean. "Pfizer's
gift elevates UConn to this elite group of institutions and demonstrates its confidence
in the research, scholarship and achievements of our faculty and students."
Pharmaceutical technology addresses product development for diverse medicinal
agents, including organic molecules, proteins and other biologics. It also encompasses
the physical and engineering sciences of drug delivery by means of multiple routes,
including oral, intravenous and injection.
Pfizer Global R&D is eager to build upon its already strong relationship with
the UConn School of Pharmacy, including several research initiatives.
"Pharmaceutical sciences researchers play a key role in the discovery and development
of new medicines for patients in needs," said Kelvin Cooper, head of Pfizer
Global Research and Development's Pharmaceutical Sciences organization. "In
today's competitive recruiting environment, Pfizer must attract the best and brightest
scientists in order to find cures for diseases like Alzheimer's, cancer and diabetes."
He added, "We are proud to partner with UConn's School of Pharmacy, and continue
to look to their program as a source of qualified researchers who will help us achieve
our mission of doing more good for people than any other company in the world."
Proceeds from the endowment will support the chair in his or her academic activities,
including pre- and post-doctoral graduate fellowships and a pharmaceutical technology
symposium. In addition, the chair's duties will include convening a working group
of representatives from the school and Pfizer in order to support the advancement
of pharmaceutical technology at UConn.
Pfizer Inc., the world's largest private biomedical research organization, has
previously endowed faculty positions in biological sciences at Stanford University
and political science at Duke University.
The Pfizer chair is the third distinguished chair at UConn. The others are the
Harold S. Schwenk Sr. Distinguished Chair in Chemistry and the Ray Neag Distinguished
Chair in Vascular Biology. UConn has a total of 47 endowed chairs and 12 endowed
professorships, including 24 chairs at the Health Center, and one chair and three
professorships at the School of Law.
In the coming weeks, a nationwide search will begin to identify candidates for
the Pfizer chair with the expectation of hiring next spring.
The UConn School of Pharmacy offers graduate programs in medicinal chemistry,
pharmaceutics, and pharmacology/toxicology as well as a six-year Doctor of Pharmacy
Pfizer Global Research and Development is headquartered in New London, Conn.,
and its largest R&D site is located in nearby Groton. Other R&D locations
include: Ann Arbor and Kalamazoo, Mich.; St. Louis, Mo.; LaJolla, Calif., Sandwich,
U.K.; and Nagoya, Japan.
June 2004 Releases